2
项与 Natural killer cell therapy(Shanghai iCELL Biotechnology) 相关的临床试验Immunotherapy of Natural Killer in HTLV-1 Associated Myelopathy
HTLV-1 Associated Myelopathy is a chronic disease of the spinal cord, caused by a virus called human T lymphotropic virus type 1（HTLV-1）. Natural Killer cells provide rapid responses to viral-infected cells, acting at around 3 days after infection, and respond to tumor formation. In this trial, the investigators aim to study the therapeutic safety and the effect on HTLV-1 virus. This in turn will improve the knowledge and understanding of the disease and should lead to better therapy.
Phase I Protocol of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission (CHR) But With Persistent/Recurrent Minimal Residual Disease (MRD) ≥60 Years or Not Eligible for Other Post-CHR Treatment Modalities
The present study aims at studying how safe and tolerable a new therapy for patients with Acute Lymphoblastic Leukemia (ALL) is.
This new therapy consists of an immunotherapy, that is an approach focusing on the immune system, and it targets ALL patients in complete remission but who may still have the disease at a cellular level (this is called 'minimal residual disease').
For any further information, please, discuss with your treating physician.
100 项与 Natural killer cell therapy(Shanghai iCELL Biotechnology) 相关的临床结果
100 项与 Natural killer cell therapy(Shanghai iCELL Biotechnology) 相关的转化医学
100 项与 Natural killer cell therapy(Shanghai iCELL Biotechnology) 相关的专利（医药）
100 项与 Natural killer cell therapy(Shanghai iCELL Biotechnology) 相关的药物交易
